secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001847903-23-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress
---------------------------------------------------------------------------

- Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.
- Net loss attributable to ordinary shareholders $43.2M for Q4 2022 vs $60.8M in Q4 2021.
- SerpinPC registrational program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected in 2023.
- First subject dosed in Phase 1/2a trial of LB101 (PD-L1xCD47 LockBody) for solid tumors.
- ORX750 nominated as product candidate for narcolepsy; preclinical data expected at scientific meeting in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/0001847903-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/cnta-20230330.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer